Paper36922828
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P and 10 others. J Transl Med, 2023. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. Papers, record 36922828. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36922828
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Immunotherapy, Adoptive | |
| T-Lymphocytes | |
| Immunotherapy | |
| Receptors, Antigen, T-Cell |
Source PubMed
References207
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34778803 | NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. | Blood Cancer Discov | 2021 | https://conductscience.org/library/papers/34778803 | PubMed |
| 2 | 32191035 | Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. | J Am Chem Soc | 2020 | https://conductscience.org/library/papers/32191035 | PubMed |
| 3 | 23032741 | Redirecting gene-modified T cells toward various cancer types using tagged antibodies. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/23032741 | PubMed |
| 4 | 23352111 | Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. | J Autoimmun | 2013 | https://conductscience.org/library/papers/23352111 | PubMed |
| 5 | 32215059 | Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. | Ther Adv Med Oncol | 2020 | https://conductscience.org/library/papers/32215059 | PubMed |
| 6 | 27329987 | A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. | Cancer Immunol Res | 2016 | https://conductscience.org/library/papers/27329987 | PubMed |
| 7 | 30889382 | Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. | Cancer Cell | 2019 | https://conductscience.org/library/papers/30889382 | PubMed |
| 8 | 31429760 | Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. | Mol Cancer | 2019 | https://conductscience.org/library/papers/31429760 | PubMed |
| 9 | 31900462 | 'Off-the-shelf' allogeneic CAR T cells: development and challenges. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/31900462 | PubMed |
| 10 | 24358223 | Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. | PLoS One | 2013 | https://conductscience.org/library/papers/24358223 | PubMed |
| 11 | 34697491 | Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. | Nat Nanotechnol | 2021 | https://conductscience.org/library/papers/34697491 | PubMed |
| 12 | 34216875 | Emerging mammalian gene switches for controlling implantable cell therapies. | Curr Opin Chem Biol | 2021 | https://conductscience.org/library/papers/34216875 | PubMed |
| 13 | 23839099 | TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. | Mol Ther Nucleic Acids | 2013 | https://conductscience.org/library/papers/23839099 | PubMed |
| 14 | 35158839 | Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158839 | PubMed |
| 15 | 10724039 | Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. | Hum Gene Ther | 2000 | https://conductscience.org/library/papers/10724039 | PubMed |
| 16 | 33113407 | Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator. | Cell Chem Biol | 2021 | https://conductscience.org/library/papers/33113407 | PubMed |
| 17 | 30046161 | TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. | Leukemia | 2018 | https://conductscience.org/library/papers/30046161 | PubMed |
| 18 | 34801727 | Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. | Mol Ther | 2022 | https://conductscience.org/library/papers/34801727 | PubMed |
| 19 | 35146940 | Light-Controllable Binary Switch Activation of CAR T Cells. | ChemMedChem | 2022 | https://conductscience.org/library/papers/35146940 | PubMed |
| 20 | 31272471 | Engineering switchable and programmable universal CARs for CAR T therapy. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31272471 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42824951 | Chimeric antigen receptor T cell therapy in autoimmune neurological disease: current status of efficacy and safety. | BMJ Neurol Open | 2026 | https://conductscience.org/library/papers/42824951 | PubMed |
| 42079032 | Hypoxic tumor microenvironment and immune cell dynamics: From metabolic reprogramming to therapeutic innovation. | Iran J Basic Med Sci | 2026 | https://conductscience.org/library/papers/42079032 | PubMed |
| 41963304 | Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41963304 | PubMed |
| 41800026 | From Ex Vivo to In Vivo: Advances in Lentiviral Vector Engineering for CAR-T Therapy. | Immune Netw | 2026 | https://conductscience.org/library/papers/41800026 | PubMed |
| 41737839 | Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors. | Small Sci | 2026 | https://conductscience.org/library/papers/41737839 | PubMed |
| 41586404 | Optogenetic engineering of synthetic and natural receptors: design principles, functional mechanisms and biomedical applications. | Regen Biomater | 2026 | https://conductscience.org/library/papers/41586404 | PubMed |
| 41454396 | Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. | J Transl Med | 2025 | https://conductscience.org/library/papers/41454396 | PubMed |
| 41369346 | Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment. | Cells | 2025 | https://conductscience.org/library/papers/41369346 | PubMed |
| 41162648 | Small-molecule control of CAR T cells. | Nat Rev Chem | 2025 | https://conductscience.org/library/papers/41162648 | PubMed |
| 40855662 | From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40855662 | PubMed |
| 40821776 | Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. | Front Immunol | 2025 | https://conductscience.org/library/papers/40821776 | PubMed |
| 40699780 | The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40699780 | PubMed |
| 40646591 | Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40646591 | PubMed |
| 40624498 | Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40624498 | PubMed |
| 40597436 | Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. | Biomark Res | 2025 | https://conductscience.org/library/papers/40597436 | PubMed |
| 40182067 | A High-Throughput, Three-Dimensional Multiple Myeloma Model Recapitulating Tumor-Stroma Interactions for CAR-Immune Cell-Mediated Cytotoxicity Assay. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40182067 | PubMed |
| 39901030 | Novel strategies to manage CAR-T cell toxicity. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/39901030 | PubMed |
| 39697333 | From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. | Front Immunol | 2024 | https://conductscience.org/library/papers/39697333 | PubMed |
| 39417449 | CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions. | Braz J Med Biol Res | 2024 | https://conductscience.org/library/papers/39417449 | PubMed |
| 39328262 | Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach. | J Extracell Biol | 2024 | https://conductscience.org/library/papers/39328262 | PubMed |
Genes68
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36922828
GET https://conductscience.org/api/papers/v1/36922828/references?page=2